ABSTRACT

Background: Little is known about the mechanism of desensitization in hypersensitivity drug reactions.

Objective: The aim of this study was to evaluate the effects of drug desensitization on some cytokine levels in patients desensitized for drug hypersensitivity reactions.

Methods: Patients with a hypersensitivity reaction to any drug for whom desensitization was planned with the culprit drug, patients who could tolerate the same drugs and healthy subjects who were not exposed to these drugs were enrolled. Bead-based Milliplex MAP multiplex technology was used to determine interleukin (IL)-4, IL-5, interferon-γ and IL-10 levels in the sera of the subjects as a baseline and 24 hours after desensitization had been completed in the patients.

Results: A total of 26 patients (16 female [61.5%]; mean age 48.46 ± 15.97 years old), 10 control patients (5 female [50%]; mean age 47.4 ± 15.4 years old) and 5 healthy subjects (3 female [60%]; mean age 34.2 ± 5.6 years old) were enrolled. Four of the 26 patients did not tolerate the procedure and were grouped as the 'unsuccessful desensitization group' whereas 22 patients successfully completed the procedure and formed the 'successful desensitization group.' Baseline cytokine levels in the 3 groups were not statistically different. Postdesensitization IL-10 levels in the successful desensitization group were significantly higher than their initial levels (p = 0.005) whereas none of the cytokine levels significantly changed in the unsuccessful desensitization group. The rise in IL-10 levels was greater in chemotherapeutic desensitizations when compared to other drugs (p = 0.006).

Conclusion: Successful desensitization independent of the hypersensitivity reaction type seems to be related to the increase of IL-10.

Keywords: Drug hypersensitivity; Desensitization; Cytokine; Interleukin-10
INTRODUCTION

Hypersensitivity reactions can be seen with various common and novel drugs and may be potentially life-threatening. As a result the patient may be relegated to secondary therapeutic options which may be less effective. Drug hypersensitivity reactions are classified as allergic and non-allergic according to the nomenclature of the task force of the European Academy of Allergy and Clinical Immunology and the American Academy of Asthma Allergy and Immunology [1]. Allergic drug hypersensitivity reactions are seen either through IgE-mediated mast cell activation or occur via mast cell activation without demonstrable IgE involvement. These reactions range widely in clinical severity from mild pruritus to anaphylaxis, which is the most serious reaction that occurs through the activation of mast cells [2]. Drug hypersensitivity reactions are also classified as immediate or nonimmediate depending on the time of the onset of symptoms [3]. In immediate reactions either IgE-mediated or a nonspecific histamine release can play a role whereas in some nonimmediate reactions a T cell-mediated mechanism has been shown [3, 4].

Drug desensitization is a therapeutic method that enables patients to take medication that previously caused hypersensitivity reactions. Desensitization to a drug by administering gradually increasing doses to reach the total cumulative therapeutic dose induces a temporary tolerance state to the drug and consequently minimizes or completely inhibits the hypersensitivity reactions [1, 2]. Desensitization is performed both in IgE-mediated reactions and also in those where drug-specific IgE cannot be demonstrated. This transient unresponsiveness yields a hypersensitive state after every re-exposure of the same drug after the drug has been discontinued, such as in treatments like chemotherapy. The tolerance state is lost within a few hours or days, depending on the drug used. Therefore, this procedure must be repeated for every drug exposure after long periods of drug intervals [1]. These longer periods are intervals significantly greater than the half-lives of the drugs [1]. In nonimmediate reactions, rapid drug desensitization is used whereas in nonimmediate reactions slower protocols are performed only in restricted clinical situations such as mild uncomplicated exanthemas and fixed drug eruptions [2, 3].

The mechanism of this procedure is partially understood with mast cells as key effector cells seeming to be the main target especially in rapid drug desensitization. In IgE mediated reactions after successful rapid desensitization to a specific drug, the skin test reactivity becomes negative confirming the inhibition of mast cell activation in this procedure [6]. This unresponsiveness state of mast cells is antigen specific and does not occur with other stimuli [1]. Recently, a reproducible in vitro mouse model of antigen-specific, rapid mast cell/IgE desensitization demonstrated a complete abolition of the acute phase of mast cell activation and a lack of late-phase mediators generation. The model suggested that the main mechanism in rapid drug desensitization is likely to be related to the stabilization of membrane bound IgE receptor carrying the responsible antigen [7].

Although it is assumed that drug tolerance does not indicate a permanent state, it is a pharmacologic tolerance as opposed to an immunologic tolerance, increasing the number of successful desensitizations in a patient markedly reduces the rate of reactions indicating perhaps a true tolerance upon repeated drug allergen exposures similar to allergen immunotherapy [8, 9]. In a few case reports and studies there are indications of the influence of regulatory cells. Therefore, studying the role of regulatory T cells in peripheral blood in desensitized patients may provide insight into the pathophysiology of the desensitized state of
this procedure [2]. Our aim was to evaluate the effects of drug desensitization on some cytokine levels in patients desensitized for immediate or nonimmediate drug hypersensitivity reactions.

**MATERIALS AND METHODS**

Patients with a hypersensitivity reaction to any drug for whom desensitization was planned with the culprit drug were included in the study. Those patients who have contraindications for drug desensitization such as those with uncontrolled asthma or cardiac disease, hemodynamically unstable patients or those who have experienced severe life-threatening immunocytotoxic reactions, vasculitis, or bullous skin diseases like Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), and drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DRESS) were excluded from the study [1]. Patients who could tolerate the same drugs and healthy subjects who were not exposed to these drugs were also enrolled as control subjects.

After written informed consent was obtained from the subjects, the recommended diagnostic tests of drug hypersensitivity to each drug were conducted. The drug hypersensitivity reactions in each patient’s medical history were classified according to recent recommendations [10]. Immediate reactions included urticaria, angioedema, rhinitis, conjunctivitis, bronchospasm, gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdominal pain and anaphylaxis that occurred within 1–6 hours after the last drug administration. Nonimmediate reactions consisted of delayed urticaria, maculopapular eruptions, fixed drug eruptions, vasculitis, toxic epidermal necrolysis, SJS, DRESS, acute generalized exanthematous pustulosis and symmetrical drug-related intertriginous and flexural exanthemas, internal organ involvements such as hepatitis, renal failure, pneumonitis, anemia, neutropenia, thrombocytopenia which occur at any time at least 1 hour after the initial drug administration.

Skin tests were conducted with skin prick tests for all drugs and were continued with intradermal tests for parenteral drugs [11]. If a definite diagnosis could not be performed after skin tests and detailed anamnesis and if the initial reaction was different from anaphylaxis and other severe cutaneous drug hypersensitivity reactions such as DRESS, TEN, or SJS, challenge tests with culprit drugs were conducted as recommended [12].

After definite hypersensitivity reactions were diagnosed, serum samples from patients, control patients and healthy subjects were collected and stored in -20°C until further analysis.

A 12-step standard rapid desensitization protocol was used for immediate reactions [2] and prolonged protocols were used for nonimmediate reactions according to the previously described protocols. Tailor made protocols were generated where no related protocols had been published for individual drugs, as shown in Table 1 [13-19].

Interleukin (IL)-4, IL-5, interferon (IFN)-γ, and IL-10 levels were determined with the bead-based Milliplex MAP multiplex technology (Millipore Corp., Billerica, MA, USA) in the peripheral serum samples of the patients before the desensitization and within 24 hours after the procedure had been completed. The same cytokine levels were also measured in control patient and healthy subjects to present baseline levels. The Ethical Commitee of Istanbul Faculty of Medicine approved the study.
Table 1: Demographic features, results of diagnostic tests, and desensitization protocols with culprit drugs in the patient group

| Patient No. | Age | Sex | Primary disease | Culprit drug (oral/parenteral) | Reaction time | Initial reaction type | Skin test results | DPT result | Published desensitization protocol/duration | Result of desensitization |
|-------------|-----|-----|-----------------|-------------------------------|---------------|-----------------------|-------------------|------------|---------------------------------------------|--------------------------|
| 1           | 67  | F   | Multiple myeloma | Lenalidomide (oral)           | Immediate     | Urticaria             | NP ID +           | Successful  | 1 day                                       | Successful               |
| 2           | 46  | F   | Endometrium cancer | Carboplatin (parenteral)      | Immediate     | Anaphylaxis           | – + NP           | Successful  | 1 day                                       | Successful               |
| 3           | 32  | F   | Congenital adrenal hyperplasia | Dexamethasone (oral) | Immediate     | Angioedema            | – – +            | No published protocol tailormade | Successful |
| 4           | 31  | F   | Iron deficiency anemia | Iron carboxymaltose (parenteral) | Immediate     | Anaphylaxis           | – + NP           | Successful  | No published protocol tailormade            | Successful               |
| 5           | 24  | M   | Testicular cancer | Bleomycin (parenteral)        | Immediate     | Urticaria             | – + NP           | Successful  | 1 day                                       | Successful               |
| 6           | 45  | F   | Iron deficiency anemia | Fe III (parenteral)          | Immediate     | Anaphylaxis           | – + NP           | Successful  | 1 day                                       | Successful               |
| 7           | 60  | F   | Ovarian cancer | Carboplatin (parenteral)      | Immediate     | Anaphylaxis           | NP NP NP          | Successful  | 1 day                                       | Successful               |
| 8           | 61  | M   | Lung cancer | Cisplatin (parenteral)        | Immediate     | Anaphylaxis           | – + NP           | Successful  | 1 day                                       | Successful               |
| 9           | 55  | F   | Endometrium cancer | Carboplatin (parenteral)      | Immediate     | Anaphylaxis           | – + NP           | Successful  | 1 day                                       | Successful               |
| 10          | 51  | F   | Multiple sclerosis | Methyl prednisolone (parenteral) | Immediate     | Anaphylaxis           | – – NP           | Successful  | 1 day                                       | Successful               |
| 11          | 55  | M   | Samter’s disease | Aspirin (oral)                | Immediate     | Respiratory exacerbation | NP NP +          | Successful  | 1 day                                       | Successful               |
| 12          | 21  | M   | Fabry disease | Fabryzyme (parenteral)        | Immediate     | Anaphylaxis           | – + NP           | Successful  | 1 day                                       | Successful               |
| 13          | 28  | F   | Gaucher | Imiglurezate (parenteral)    | Immediate     | Urticaria and angioedema | – + NP          | Successful  | 1 day                                       | Successful               |
| 14          | 38  | F   | Lymphoma | Rituximab (parenteral)        | Immediate     | Urticaria and angioedema | – – +            | Successful  | 1 day                                       | Successful               |
| 15          | 66  | M   | Coronary artery disease | Aspirin (oral)               | Immediate     | Urticaria             | NP NP +          | Successful  | 1 day                                       | Successful               |
| 16          | 54  | F   | Colon cancer | Oxaliplatin (parenteral)      | Immediate     | Anaphylaxis           | – + NP           | Successful  | 1 day                                       | Successful               |
| 17          | 74  | F   | Multiple myeloma | Lenalidomide (oral)          | NonImmediate   | Urticaria exacerbation | NP NP +          | Successful  | 6 weeks                                      | Successful               |
| 18          | 51  | M   | Soft tissue sarcoma | Pazopanib (oral)             | NonImmediate   | Maculopapular rash    | NP NP +          | Successful  | 28 days (modified)                          | Successful               |
| 19          | 43  | F   | Graves’ disease | Thromazol (oral)             | NonImmediate   | Urticaria exacerbation | NP NP +          | Successful  | No published protocol tailormade            | Successful               |
| 20          | 65  | M   | Multiple myeloma | Lenalidomide (oral)          | NonImmediate   | Maculopapular rash    | NP NP +          | Successful  | 16 days                                      | Successful               |
| 21          | 74  | M   | Colon cancer | Capcitabine (oral)           | NonImmediate   | Maculopapular rash    | NP NP +          | Successful  | 16 days                                      | Successful               |
| 22          | 36  | F   | Multiple sclerosis | Methyl prednisolone (parenteral) | Immediate     | Urticaria             | – + NP           | Successful  | Castells [14]                                | Successful               |
| 23          | 55  | M   | Samter’s disease | Aspirin (oral)               | Immediate     | Respiratory exacerbation, urticaria | NP NP +          | Successful  | 1 day                                       | Successful               |
| 24          | 35  | F   | Samter’s disease | Aspirin (oral)               | Immediate     | Respiratory exacerbation, urticaria | NP NP +          | Successful  | 1 day                                       | Successful               |
| 25          | 26  | M   | Chronic myeloid leukemia | Nilotinib (oral)             | NonImmediate   | Maculopapular rash    | NP NP +          | Successful  | 16 days                                      | Successful               |
| 26          | 67  | M   | Multiple myeloma | Lenalidomide (oral)          | NonImmediate   | Urticaria             | NP NP +          | Successful  | 1 day                                       | Successful               |

ID, intradermal skin test; DPT, drug provocation test; NP, not performed.
Statistical analysis
The cytokine levels measured in the 3 groups of subjects were nonparametric variables and were therefore analyzed with a Kruskal-Wallis H test. The analysis of cytokine levels before and after desensitization in the patient group was performed with a Wilcoxon Signed Ranks test. A Mann-Whitney U test was used to compare the cytokine levels in chemotherapeutic desensitization with other drug desensitizations. Results were evaluated at a $p < 0.05$ significance level.

RESULTS
A total of 26 patients (16 female [61.5%]; mean age $48.46 \pm 15.97$ years old) for whom a desensitization protocol was planned for hypersensitivity reactions to certain drugs were included in the study. Table 1 shows the culprit drug, the primary disease, the type of hypersensitivity reaction in their history, the skin test and the provocation test results, and the outcome of the desensitization for each patient. All of the provocation tests except for 2 were previously published and were cited in Table 1. We used tailor made desensitization protocols for dexamethasone and thyromazol since we could not find a published protocol for either.

During the desensitization procedure, 2 patients experienced dyspepsia and urticaria with acetylsalicylic acid and did not want to continue the procedure. One patient experienced a maculopapular rash with a low dose of nilotinib and could not tolerate the therapeutically effective dose. Another patient who experienced urticaria with lenalidomide during the procedure did not give consent for further desensitization. As a result these four patients were grouped as the ‘unsuccessful desensitization group’ whereas 22 patients successfully completed the procedure and formed the ‘successful desensitization group’.

Additionally, 10 patients (5 female [50%]; mean age $47.4 \pm 15.4$ years old) who could tolerate the same group of drugs were included. Six of them had malignancy including colon, testicular, breast and lung cancers, lymphoma or multiple myeloma and could well tolerate methylprednisolone, aspirin, capecitabine, bleomycine, carboplatin, cisplatin, lenolidomide or rituximab. One patient with Basedow Graves disease could tolerate thyromazol. Another patient diagnosed with Fabry Disease could use imigluseraze and 1 patient with iron deficiency anemia could tolerate parenteral iron. 5 healthy subjects (3 female [60%]; mean age $34.2 \pm 5.6$ years old) were also enrolled in the study.

Table 2 demonstrates the baseline cytokine levels in patients, control patients and healthy controls. There was not a statistically significant difference between baseline cytokine levels in three the groups. Additionally, a significant difference in baseline levels was not observed among patients with malignancy and those with other primary diseases.

When postdesensitization cytokine levels were measured, IL-10 levels were significantly higher than their initial levels in the successful desensitization group ($p = 0.005$) whereas the other cytokine levels were not significantly different. In the unsuccessful desensitization group, none of the cytokine levels significantly changed after the attempt of desensitization (Table 3).

The rise in IL-10 levels was greater in chemotherapeutic desensitization than the desensitization with other drugs ($p = 0.006$) (Table 4). Demographic factors, the primary disease or the reaction type in the history were not related to the rise in IL-10.
DISCUSSION

This is the first study evaluating cytokine involvement in desensitization to various drugs in different clinical pictures and presents the absolute rise in IL-10 within 24 hours after successful procedures regardless of the hypersensitivity reaction type or the culprit drug.

Most of our knowledge about the mechanism of desensitization relies on the findings of rapid desensitization. This method was found to be effective both in IgE mediated and in non-IgE mediated immediate reactions due to direct mediator release from mast cells [20]. Therefore,

| Table 2. Comparison of serum baseline cytokine levels of the study groups |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Baseline cytokine level (pg/mL) | Successful desensitization | Unsuccessful desensitization | Patient controls | Healthy controls |
| IFN-γ | 0.16 (0.15–2.28) | 0.79 (0.15–2.28) | 0.16 (0.14–5.88) | 0.16 (0.14–4.11) |
| IL-4 | 0.30 (0.22–28.15) | 0.72 (0.30–3.18) | 0.37 (0.22–53.23) | 0.30 (0.30–9.51) |
| IL-5 | 1.17 (0.93–3.45) | 1.34 (0.93–8.80) | 1.21 (0.84–3.03) | 0.93 (0.77–43.98) |
| IL-10 | 2.26 (0.35–12.12) | 2.93 (1.37–4.29) | 1.87 (0.32–594.38) | 1.60 (0.32–79.55) |

Values are presented as median (range).

IFN, interferon; IL, interleukin; NS, not significant.

| Table 3. Comparison of postdesensitization cytokine levels with initial values |
|-----------------------------|-----------------------------|-----------------------------|
| Cytokine level (pg/mL) | Patients |
| Successful desensitization | Unsuccessful desensitization |
| IFN-γ | Baseline | 0.16 (0.15–2.28) | 0.79 (0.15–2.28) |
| | After desensitization | 0.19 (0.14–19.84) | 0.27 (0.15–2.28) |
| IL-4 | Baseline | 0.30 (0.22–28.15) | 0.72 (0.30–3.18) |
| | After desensitization | 0.30 (0.22–46.82) | 0.75 (0.30–3.18) |
| IL-5 | Baseline | 1.17 (0.93–3.45) | 1.34 (0.93–8.80) |
| | After desensitization | 1.09 (0.84–12.12) | 1.40 (0.93–8.81) |
| IL-10 | Baseline | 2.26* (0.35–12.12) | 2.93 (1.37–4.29) |
| | After desensitization | 5.39* (0.35–989.35) | 2.42 (1.39–4.26) |

Values are presented as median (range).

IFN, interferon; IL, interleukin; NS, not significant.

*p = 0.005.

| Table 4. Comparison of cytokine levels in chemotherapeutic desensitization with desensitizations for other drugs |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Cytokine levels (pg/mL) | Patients | Chemotherapeutic desensitization | Desensitization with other drugs |
| IFN-γ | Baseline | 0.22 (0.15–2.28) | 0.16 (0.15–2.28) |
| | After desensitization | 0.25 (0.14–19.84) | 0.17 (0.14–2.28) |
| IL-4 | Baseline | 0.45 (0.30–3.18) | 0.30 (0.22–28.15) |
| | After desensitization | 0.30 (0.22–3.18) | 0.30 (0.22–46.82) |
| IL-5 | Baseline | 1.17 (0.93–2.20) | 1.21 (0.93–8.80) |
| | After desensitization | 1.25 (0.93–12.12) | 1.05 (0.84–8.80) |
| IL-10 | Baseline | 2.57* (0.35–7.33) | 2.26 (0.45–12.12) |
| | After desensitization | 9.00* (0.35–989.35) | 1.73 (0.45–17.56) |
| | Difference before and after desensitization | −5.80* (−987.48 to 0.81) | −0.01 (−14.26 to 1.57) |

Values are presented as median (range).

IFN, interferon; IL, interleukin; NS, not significant.

*p = 0.006.
the role of mast cells in immediate reactions and their unresponsive states were examined in previous studies [21, 22]. Three hypotheses were asserted: depletion of activating signal transduction components, subthreshold depletion of mediators, and internalization of FcεRI through progressive cross-linking at a low antigen concentration [5]. Recently, a mouse model indicated that the main mechanism responsible for the unresponsiveness of mast cells is the impairment of the internalization of IgE and FcεRIα resulting in the bondage of the cross-linked receptors to the cell membrane. This unresponsiveness of mast cells through rapid desensitization was shown to be antigen specific and did not induce anergy [7].

Immediate desensitization is not known to prevent the occurrence of non-IgE-mediated reactions, like maculopapular eruptions or severe cutaneous bullous reactions [1]. An important point to be addressed is that in most nonimmediate reactions sensitization cannot be documented by positive skin tests because of their low sensitivity and specificity and therefore the underlying mechanism in these reactions is largely unknown [23, 24]. Slow desensitization protocols can be successfully performed in some nonimmediate reactions and although not completely understood, cells other than mast cells are likely to be involved.

T cells and their cytokines were examined in a few studies dealing with specific illnesses or in rare case reports of those who underwent drug desensitization. In a recent study in patients with aspirin-exacerbated respiratory disease (AERD), the effect of aspirin desensitization on T-cell cytokines was examined and revealed no difference in the percentage of CD4+ T lymphocytes expressing IL-2, IL-4, and IFN-γ levels 1 month after desensitization when compared to baseline levels [25]. Although a significant difference could not be found in the first month of tolerance, perhaps long-term effects could have been seen in the following months, which was not mentioned in the study. In another study of patients with AERD who underwent aspirin desensitization, intracellular IL-10 and IFN-γ levels decreased after 1 month of desensitization and came to a level similar to healthy subjects [26]. The authors tried to explain the decrease in intracellular IL-10 as a result of the control of inflammation and suggested that IFN-γ and IL-10 expression in CD4+ T lymphocytes might be related to the pathogenesis of AERD and the mechanism of aspirin desensitization. We can speculate in accordance with this finding, that the secreted levels of these cytokines might have increased in the serum although the authors did not measure the levels. If the cytokines in the patients’ sera could have been measured, a finding similar to our study might have been expected.

These studies evaluating T-cell related cytokines in aspirin desensitization provide limited information about the role of T cells, however the low number of patients evaluated in these studies and desensitization only to aspirin for a specific disease does not allow further understanding of the mechanism of all types of drug desensitization.

Teraki and Shiohara [23] showed that in allopurinol induced fixed drug eruptions, the number of CD25+CD4+ T cells in the lesion increased after desensitization whereas the number of CD8+ T cells decreased from 91% of CD3+ cells to 35% during the procedure. They proposed that the peripheral Treg cells migrating into the lesion might have a suppressive effect on the effector function of CD8+ T cells in the lesion. In another case report, an increase of IL-10 and IL-6 levels was observed in the culture of peripheral blood mononuclear cell one month after the tolerance induced by allopurinol desensitization in a patient who had experienced a fixed drug eruption due to allopurinol [27]. These 2 patients as examples of the desensitization of a nonimmediate drug eruption revealed the possible role of Treg cells in the induction of desensitization to such reactions.
Regulatory CD25+CD4+ T cells suppress immune responses via cell-to-cell interactions and/or the production of cytokines such as IL-10 and transforming growth factor-β [28, 29] which is also demonstrated in allergen immunotherapy. Therefore the presence of these cells or their cytokines in the blood samples or skin biopsy specimens of the patients can provide further information about the mechanism of drug desensitization. We observed the cytokines known to be secreted primarily from Th2, Th1, and peripheral Treg cells. Although we know that complex and diverse clinical manifestations caused by the functional heterogeneity of T cells occur in immediate and nonimmediate hypersensitivity reactions due to drugs, it is interesting to observe the increase in IL-10 in different types of reactions. The higher levels of IL-10 observed in chemotherapeutic desensitizations is also of note.

Our study has several limitations. Cytokine levels were measured only after the completion of the procedure whereas subsequent measurements were not taken. Each procedure was the first attempted desensitization for that patient so the effect of multiple desensitization was not observed. It was previously shown that patients receiving multiple desensitizations showed a decrease in the severity and frequency of reactions with subsequent procedures which may better explain the existence of immunologic tolerance in drug desensitizations [8]. Although the diversity of the drugs and the reactions are acceptable in our study, the low number of control subjects affects the significance of our findings.

In conclusion, the successful desensitization independent of the hypersensitivity reaction type seems to be related with the increase of IL-10. In order to further understand the mechanism of successful desensitization, regulatory mechanisms should be examined.

REFERENCES

1. Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A, Campi P, Sanz ML, Castells M, Demoly P, Pichler WJ; European Network of Drug Allergy and the EAACI interest group on drug hypersensitivity. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy 2010;65:1357-66.

2. Castells M, Sancho-Serra Mdel C, Simarro M. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol Immunother 2012;61:1575-84.

3. Scherer K, Brockow K, Aberer W, Gooi JH, Demoly P, Romano A, Schnyder B, Whitaker P, Cernadas JS, Bircher AJ; ENDA, the European Network on Drug Allergy and the EAACI Drug Allergy Interest Group. Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013;68:844-52.

4. Pichler WJ. Drug hypersensitivity reactions: classification and relationship to T-cell activation. In: Pichler WJ, editor. Drug hypersensitivity. Basel: Karger; 2007:168-89.

5. Liu A, Fanning L, Chong H, Fernandez J, Sloane D, Sancho-Serra M, Castells M. Desensitization regimens for drug allergy: state of the art in the 21st century. Clin Exp Allergy 2011;41:1679-89.

6. Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004;95:370-6.

7. Sancho-Serra Mdel C, Simarro M, Castells M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcεRI internalization. Eur J Immunol 2011;41:1004-13.
8. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RJ, Rao JJ, Berlin ST, Campos SM, Matulonis UA. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574-80.

9. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009;124:1259-66.

10. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, Khan DA, Lang DM, Park HS, Pichler W, Sanchez-Borges M, Shiohara T, Thong BY. International Consensus on drug allergy. Allergy 2014;69:420-37.

11. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, Bircher A, Blanca M, Bonadonna B, Campi P, Castro E, Cernadas JR, Chiriac AM, Demoly P, Grosber M, Gooi J, Lombardo C, Mertes PM, Mosbech H, Nasser S, Pagani M, Ring J, Romano A, Scherer K, Schnyder B, Testi S, Torres M, Trautmann A, Terreehorst I; ENDA/EAACI Drug Allergy Interest Group. Skin test concentrations for systematically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013;68:702-12.

12. Brockow K, Przybilla B, Aberer W, Birch A, Brehler R, Dickel H, Fuchs T, Jakob T, Lange L, Pfützner W, Mockenhaupt M, Ott H, Pfaar O, Ring J, Sachs B, Sitter H, Trautmann A, Treudler R, Turet M, Wurpts G, Zuberbier T, Merk HF. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). Allergo J Int 2015;24:94-105.

13. Phillips J, Kujawa J, Davis-Lorton M, Hindenburg A. Successful desensitization in a patient with lenalidomide hypersensitivity. Am J Hematol 2007;82:1030.

14. Castells M. Rapid desensitization for hypersensitivity reactions to chemotherapy agents. Curr Opin Allergy Clin Immunol 2006;6:271-7.

15. Rodríguez-Jiménez B, Domínguez-Ortega J, Nuñez-Acevedo B, Cava-Sumner B, Kindelan-Recarte C, Montojo-Guillén C. Rapid iron desensitization after generalized urticaria and facial angioedema. J Investig Allergol Clin Immunol 2014;24:69-71.

16. Hope AP, Woessner KA, Simon RA, Stevenson DD. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2009;123:406-10.

17. Erdoğdu D, Gelinic A, Canbaz B, Colakoğlu B, Büyükköztüürk S, Tanakol R. Successful desensitization to imiglucerase of an adult patient diagnosed with type I Gaucher disease. Int Arch Allergy Immunol 2013;160:215-7.

18. Lee MJ, Wickner P, Fanning L, Schlossman R, Richardson P, Laubach J, Castells M. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. Br J Haematol 2014;167:127-31.

19. Demir S, Olgac M, Saglam S, Gelinic A, Colakoğlu B, Buyukozturk S. Successful capectabine desensitization for a delayed-type hypersensitivity reaction. J Investig Allergol Clin Immunol 2016;26:66-7.

20. Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 2006;6:476-81.

21. Shalit M, Levi-Schaffer F. Challenge of mast cells with increasing amounts of antigen induces desensitization. Clin Exp Allergy 1995;25:896-902.
22. Kepley CL. Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels. Int Arch Allergy Immunol 2005;138:29-39.

23. Teraki Y, Shiohara T. Successful desensitization to fixed drug eruption: the presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization. Dermatology 2004;209:29-32.

24. Barbaud A. Skin testing in delayed reactions to drugs. Immunol Allergy Clin North Am 2009;29:517-35.

25. Aktas A, Kurt E, Gulbas Z. Cytokine expression before and after aspirin desensitization therapy in aspirin-exacerbated respiratory disease. Inflammation 2013;36:1553-9.

26. Aksu K, Kurt E, Alatas Ö, Gülbas Z. Effect of aspirin desensitization on T-cell cytokines and plasma lipoxins in aspirin-exacerbated respiratory disease. Allergy Asthma Proc 2014;35:148-55.

27. Martínez-Aranguren R, Gamboa PM, García-Lirio E, Alonso A, Sanz ML. In vitro cytokine production after in vivo desensitization in an allopurinol-induced delayed allergic reaction. Ann Allergy Asthma Immunol 2012;108:280-4.

28. Kingsley CI, Karim M, Bushell AR, Wood KJ. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002;168:1080-6.

29. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001;194:629-44.